Search General Info
Search Education
Search Partnering Companies

Ken Batchelor, PhD

Research Triangle Park, North Carolina, United States
Ken Batchelor has more than 35 years of experience in drug discovery and development in the pharmaceutical and biotech industries, including 10 years as SVP for Drug Discovery at GSK.
Ken is co-inventor of Dutasteride, a blockbuster drug for the treatment of BPH, and was responsible for the discovery and early development of multiple drugs for cancer (Tykerb and Votrient), T2D (Remogliflozin, denagliptin, Tanzeum and farglitazar) and anti-virals (Lexiva and maribavir).
Ken founded NovaTarg Therapeutics to discover and develop new drugs for metabolic diseases and cancer. Creating a proprietary cell-based screening platform that has supported the discovery of novel biguanides (NT1238 and NT1195). An approach that has seen NovaTarg optimize a valuable drug class of which metformin is the prototype and so far only member.
Ken is now involved in the progression of NovaTarg's drug candidates, where his experience in early drug development is central to company success.
Speaking In
[Available On-Demand]
NovaTarg is a drug discovery and development organization focused on new medicines to treat…